The Biostatistics Core will provide the statistical support for clinical, animal, tissue-based, and cell line investigations in pediatric neuroblastoma supported by this Program Project Grant (PPG). Sound design and statistical input in the planning, conduct, and interpretation of experiments promote the two aspects of translational research: (1) rapid incorporation of significant laboratory findings into the development of data-based therapeutic clinical studies and (2) the development of questions and hypotheses based on clinical findings which can be further investigated in the laboratory. With this in mind, there are three aims of the Biostatistics Core. 1. Provide statistical expertise in the early planning and in the experimental design of laboratory and clinical research a. in vitro experiments (e.g. cell line drug response) b. in vivo experiments (e.g. mouse clinical trials) c. Studies/experiments using specimens from patients (e.g. Affy HuEx) d. NANT Clinical Trials (early phase clinical trials) 2. Provide formal statistical analyses for these experiments and studies 3. Oversee data collection, study progress, data quality control a. With Project 4. oversee the further development and maintenance of the NANT Phase l/ll database.

Public Health Relevance

Statistical collaboration and formal statistical design considerations are essential to the planning of experiments {in vitro and in vivo), clinical trials, and observational studies. Appropriate design is necessary to ensure efficient, feasible studies that will yield meaningful results;appropriate (statistical) analysis, ensures that results are correctly interpreted, and maximizes the information learned.

National Institute of Health (NIH)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital of Los Angeles
Los Angeles
United States
Zip Code
Johnson, Brett E; Mazor, Tali; Hong, Chibo et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-93
Borriello, Lucia; DeClerck, Yves A (2014) [Tumor microenvironment and therapeutic resistance process]. Med Sci (Paris) 30:445-51
Gustafson, William Clay; Meyerowitz, Justin Gabriel; Nekritz, Erin A et al. (2014) Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26:414-27
Kang, Min H; Villablanca, Judith G; Glade Bender, Julia L et al. (2014) Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes 7:256
Solari, Valeria; Borriello, Lucia; Turcatel, Gianluca et al. (2014) MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. Cancer Res 74:5999-6009
Sos, Martin L; Levin, Rebecca S; Gordan, John D et al. (2014) Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep 8:1037-48
Marshall, Glenn M; Carter, Daniel R; Cheung, Belamy B et al. (2014) The prenatal origins of cancer. Nat Rev Cancer 14:277-89
Ilkanizadeh, Shirin; Lau, Jasmine; Huang, Miller et al. (2014) Glial progenitors as targets for transformation in glioma. Adv Cancer Res 121:1-65
Bergfeld, Scott A; Blavier, Laurence; DeClerck, Yves A (2014) Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Ther 13:962-75
Chen, Justin; Weiss, William A (2014) When deletions gain functions: commandeering epigenetic mechanisms. Cancer Cell 26:160-1

Showing the most recent 10 out of 106 publications